By Admin LinkedIn Google Plus Twitter
European Medicines Agency and EMA Guidelines
Guidelines
- Search for scientific guidelines
- Quality guidelines
- Quality of medicines questions and answers: Introduction
- Biological guidelines
- Non-clinical guidelines
- Clinical efficacy and safety guidelines
- Multidisciplinary guidelines
- International Conference on Harmonisation (ICH) guidelines
Quality guidelines
- Active substance
- Manufacturing
- Impurities
- Specifications, analytical procedures and analytical validation
- Excipients
- Packaging
- Stability
- Pharmaceutical development
- Specific types of products
- Post-approval change management protocols
- Herbal medicinal products
General regulatory and procedural guidance
|
- Pre-marketing authorisation
|
- Pre-submission
- Data exclusivity/ Generics/ Biosimilars
- Dossier submission requirements
|
- Dossier format
- Application and evaluation
- Post-opinion
|
- Post-marketing authorisation
|
- General
- Dossier submission requirements
- Type IA variations
- Type IB variations
- Type II variations
- Type II variations vs Extension applications
- Changing the (invented) name of a centrally authorised medicinal product
- Annual re-assessment
- Follow-up Measures / Specific Obligations
|
- Renewals
- PSURs
- Transfer of marketing authorisation
- Transparency
- Article 61(3) Notifications
- Marketing and cessation notification
- Sunset clause monitoring
- Urgent safety restrictions
|
- Product information
- Scientific advice and protocol assistance
- Innovation Task Force (ITF)
- Small and Medium-sized Enterprises (SME)
- Paediatrics
- Orphans
- Herbal medicinal products
- Referral procedures
- Article 58 applications
- Pharmacovigilance
- Advanced therapies
- Inspections
- Parallel distribution
- Ancillary medicinal substances
- New countries/EFTA
|
